Find it in seconds.
MRK
31 filings
Timeline Columns Start Research 8-K Categories
10-Q Quarterly 8
2025 Q4
2025-11-05 · 124 pg (+10)
Q3 2025 Results
View Filing →
2025 Q3
2025-08-05 · 112 pg (+3)
Q2 2025 Results
View Filing →
2025 Q2
2025-05-02 · 83 pg (0)
Q1 2025 Results
Financial data not available in provided content
View Filing →
2024 Q4
2024-11-06 · 114 pg (+1)
Q3 2024 Results
View Filing →
2024 Q3
2024-08-05 · 109 pg (+6)
Q2 2024 Results
Financial data not available in provided content
View Filing →
2024 Q2
2024-05-03 · 83 pg
Q1 2024 Results
View Filing →
2023 Q4
2023-11-03 · 113 pg
Q3 2023 Results
View Filing →
2023 Q3
2023-08-07 · 103 pg
Q2 2023 Results
View Filing →
10-K Annual 2
2025 Q1
2025-02-25 · 268 pg (+3)
FY24 2024 Results
Data insufficient - no clear revenue or EPS figures available in provided content
📌 Data insufficient - filing content appears to be primarily XBRL taxonomy references without substantive financial data or business highlights
View Filing →
2024 Q1
2024-02-26 · 265 pg
FY 2023 Results
📌 Multiple strategic partnerships and acquisitions including Daiichi Sankyo antibody-drug conjugate collaboration (October 2023), Prometheus Biosciences acquisition (June 2023), and planned Harpoon Therapeutics acquisition (forecast completion by June 2024)
View Filing →
8-K Events 19
2025 Q4
2025-12-04 · 2 pg
Closed underwritten public offering of $6.5B worth of debt securities
$6.5 billion
View Filing →
2025-10-30
Q3 2025 Earnings Released
Revenue and financial results disclosed for Q3 2025
View Filing →
2025 Q3
2025-09-09
Debt Offering
$6B notes offering with rates from floating to 5.7%
View Filing →
2025-07-29
Q2 Earnings + $3B Restructuring Program
$3B restructuring costs, $1.7B annual savings by 2027
View Filing →
2025 Q2
2025-05-29
Annual Shareholder Meeting
13 directors elected, executive comp approved, 4 shareholder proposals rejected
View Filing →
2025-04-24
Q1 2025 Earnings
First quarter 2025 earnings results
View Filing →
2025 Q1
2025-02-04
Q4 2024 Earnings
Fourth quarter and year end 2024 results reported
View Filing →
2024 Q4
2024-11-22
New Director Elected, Bylaws Amended
Lal Karsanbhai elected to Board effective Jan 1, 2025; indemnification provisions updated
View Filing →
2024-10-31
Q3 Earnings
Q3 2024 earnings reported
View Filing →
2024 Q3
2024-07-30
Q2 2024 Earnings
Second quarter 2024 earnings results
View Filing →
2024 Q2
2024-05-30
€3.4B Debt Offering & Annual Meeting
€3.4B notes issued (3.25%-3.75% rates, 2032-2054 maturities); all directors re-elected
View Filing →
2024-04-25
Q1 2024 Earnings
Q1 2024 financial results reported
View Filing →
2024 Q1
2024-02-20
Director Retirement
Peter C. Wendell retiring from Board at 2024 Annual Meeting (May 28, 2024)
View Filing →
2024-02-01
Q4 Earnings + $4B Restructuring Program
$4B restructuring costs through 2031, 60% non-cash
View Filing →
2023 Q4
2023-11-28
Global Controller Change
Rita Karachun resigned, Dalton Smart III appointed effective Dec 4, 2023
View Filing →
2023-10-26
Q3 2023 Earnings
Third quarter 2023 earnings results reported
View Filing →
2023 Q3
2023-08-01
Q2 2023 Earnings
Second quarter 2023 earnings reported
View Filing →
2023 Q2
2023-05-26
Annual Shareholder Meeting
13 directors elected, executive compensation approved 91.30%
View Filing →
2023-05-17
Debt Offering
$5B multi-tranche notes offering, rates 4.05%-5.15%
View Filing →